$4.03
-0.23 (-5.40%)
Open$4.01
Previous Close$4.26
Day High$4.36
Day Low$3.82
52W High$32.34
52W Low$13.36
Volume—
Avg Volume375.8K
Market Cap36.64M
P/E Ratio20.74
EPS$1.24
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+664.8% upside
Current
$4.03
$4.03
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.40M | 9.97M | 8.09M |
| Net Income | 1.68M | 1.79M | 1.56M |
| Profit Margin | 16.1% | 17.9% | 19.2% |
| EBITDA | 3.32M | 3.17M | 2.28M |
| Free Cash Flow | 838.7K | 1.16M | 856.1K |
| Rev Growth | +2.0% | -1.5% | -6.8% |
| Debt/Equity | 0.33 | 0.34 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |